A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
Works matching IS 01676997 AND DT 2010 AND VI 28 AND IP 1
Results: 15
1
2
Differential gene expression triggered by highly cytotoxic alpha-Emitter-immunoconjugates in gastric cancer cells.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
3
A novel DNA intercalator, butylamino-pyrimido[4',5':4,5]selenolo(2,3-b)quinoline, induces cell cycle arrest and apoptosis in leukemic cells.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
4
Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report.
- Published in:
- 2010
- By:
- Publication type:
- Report
5
A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 91, doi. 10.1007/s10637-009-9230-z
- By:
- Publication type:
- Article
6
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 76, doi. 10.1007/s10637-009-9224-x
- By:
- Publication type:
- Article
7
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 14, doi. 10.1007/s10637-008-9208-2
- By:
- Publication type:
- Article
8
Differential gene expression triggered by highly cytotoxic α-Emitter-immunoconjugates in gastric cancer cells.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 49, doi. 10.1007/s10637-008-9214-4
- By:
- Publication type:
- Article
9
B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 26, doi. 10.1007/s10637-008-9211-7
- By:
- Publication type:
- Article
10
A novel DNA intercalator, butylamino-pyrimido[4′,5′:4,5]selenolo(2,3-b)quinoline, induces cell cycle arrest and apoptosis in leukemic cells.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 35, doi. 10.1007/s10637-008-9212-6
- By:
- Publication type:
- Article
11
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 61, doi. 10.1007/s10637-008-9216-2
- By:
- Publication type:
- Article
12
Esophageal ulcer in a patient who received bevacizumab.
- Published in:
- 2010
- By:
- Publication type:
- Report
13
Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 20, doi. 10.1007/s10637-008-9209-1
- By:
- Publication type:
- Article
14
Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 1, doi. 10.1007/s10637-008-9207-3
- By:
- Publication type:
- Article
15
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 1, p. 83, doi. 10.1007/s10637-009-9229-5
- By:
- Publication type:
- Article